Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Reneuron Share Price
  4. Reneuron Share Regulatory News
  5. Director Declaration

Pin to quick picksReneuron Regulatory News (RENE)

Reneuron Information
  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Declaration

17 Dec 2021 14:00

RNS Number : 0818W
ReNeuron Group plc
17 December 2021
 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Director Declaration

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Iain Ross, Chairman, has advised the Company that Palla Pharma Limited (ASX:PAL), of which he is a Non-Executive Director, has entered into voluntary administration on 17 December 2021.

 

The ASX announcement can be viewed in full via the following link:

https://www.asxonline.com/public/notices/2021/December/1861.21.12.html 

 

This announcement is made in accordance with Rule 17 and schedule 2, paragraph (g) of the AIM Rules for Companies.

 

ENDS

 

Contacts:

 

ReNeuron

www.reneuron.com/investors

Olav Hellebø, Chief Executive Officer

Catherine Isted, Chief Financial Officer

Via Walbrook PR

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

 

 

 

Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)

 

Stefano Aquilino (Sales & Corporate Broking)

 

 

 

Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

   

 

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNGPGUAPUPGGWM
12345678910
Date   Source Headline
7th Oct 20227:00 amRNSPositive Exosome data presented at US conference
22nd Sep 20227:00 amRNSReNeuron to present new data at Exosome conference
14th Sep 20227:00 amRNSDirectorate and Executive Changes
9th Sep 202210:58 amRNSResult of AGM
2nd Sep 202211:01 amRNSDirector/PDMR Shareholding
1st Sep 20227:00 amRNSBlock Listing Review and Total Voting Rights
15th Aug 20223:25 pmRNSPosting of AR & Accounts & Notice of AGM
1st Aug 20227:00 amRNSDirectorate Change
15th Jul 20227:00 amRNSGrant of Options
14th Jul 20227:00 amRNSShare Purchase by a Director
13th Jul 20227:00 amRNSShare Purchase by a Director
4th Jul 20227:00 amRNSPreliminary Results
1st Jul 20227:00 amRNSFosun Tech Transfer and Supply Agreement update
20th Jun 20227:00 amRNSNotice of Results
3rd May 20227:00 amRNSReNeuron to present at ISCT 2022 in San Francisco
25th Apr 20227:00 amRNSDirector Declaration
23rd Mar 20227:00 amRNSHolding(s) in Company
22nd Mar 20227:01 amRNSDirectorate Changes
22nd Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
8th Mar 20227:00 amRNSBlock Listing Review and Total Voting Rights
7th Mar 20224:00 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSDirector exit arrangements
11th Feb 20224:41 pmRNSSecond Price Monitoring Extn
11th Feb 20224:36 pmRNSPrice Monitoring Extension
11th Feb 20222:38 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSDirector Change
10th Feb 20229:49 amRNSHolding(s) in Company
9th Feb 202211:59 amRNSHolding(s) in Company
4th Feb 20225:17 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSInvestor Presentation
26th Jan 20222:06 pmRNSSecond Price Monitoring Extn
26th Jan 20222:01 pmRNSPrice Monitoring Extension
18th Jan 20224:35 pmRNSPrice Monitoring Extension
18th Jan 20222:06 pmRNSSecond Price Monitoring Extn
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:05 amRNSSecond Price Monitoring Extn
18th Jan 202211:00 amRNSPrice Monitoring Extension
18th Jan 20229:05 amRNSSecond Price Monitoring Extn
18th Jan 20229:00 amRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSStrategic update
13th Jan 20227:00 amRNSAdditional agreement with Fosun Pharma for CTX
11th Jan 20227:00 amRNSNew Senior Appointment
17th Dec 20212:00 pmRNSDirector Declaration
30th Nov 20217:00 amRNSInterim Results
19th Nov 20217:00 amRNSCTX-iPSC platform data shows commerical potential
18th Nov 20217:00 amRNSNotice of Results
1st Nov 20217:00 amRNSTotal Voting Rights
26th Oct 20213:09 pmRNSDirector exit arrangements
26th Oct 20217:00 amRNSCollaboration agreement with UCL
21st Oct 20217:00 amRNSDirector Share Purchase
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.